• LAST PRICE
    37.6800
  • TODAY'S CHANGE (%)
    Trending Down-0.1500 (-0.3965%)
  • Bid / Lots
    35.0000/ 1
  • Ask / Lots
    50.0000/ 1
  • Open / Previous Close
    37.4900 / 37.8300
  • Day Range
    Low 37.4633
    High 38.2800
  • 52 Week Range
    Low 27.9850
    High 50.9900
  • Volume
    355,964
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 37.83
TimeVolumeXENE
09:32 ET74337.49
09:34 ET10037.57
09:36 ET70037.53
09:38 ET20037.5
09:45 ET40037.4633
09:48 ET10037.47
10:01 ET10037.67
10:10 ET10037.67
10:15 ET40037.79
10:17 ET10020037.73
10:19 ET40037.74
10:21 ET17337.721
10:24 ET10037.83
10:26 ET30037.795
10:32 ET50038.13
10:33 ET40038.03
10:35 ET20038.1
10:46 ET48338.003
10:48 ET72938.17
10:55 ET73638.15
11:00 ET10038.01
11:02 ET30038.01
11:04 ET10038.02
11:08 ET10038.045
11:15 ET14638.01
11:20 ET115837.98
11:22 ET10037.985
11:24 ET20038.04
11:29 ET52538.1
11:31 ET29138.002
11:33 ET10038.075
11:38 ET10038.085
11:40 ET22438.04
11:44 ET10038.115
11:45 ET10038.192
11:51 ET172838.2
11:54 ET10038.28
11:56 ET70038.115
12:00 ET10038.08
12:02 ET20038.11
12:07 ET30038.06
12:09 ET503638.05
12:12 ET57238.01
12:16 ET10038.04
12:18 ET444338.04
12:20 ET33638.01
12:21 ET723337.85
12:25 ET30037.84
12:27 ET10037.83
12:30 ET30037.84
12:32 ET10037.89
12:38 ET40037.76
12:50 ET57137.49
12:52 ET130037.64
12:54 ET20037.61
12:56 ET10337.6
12:57 ET10037.68
12:59 ET10037.62
01:01 ET20037.6
01:17 ET10037.69
01:21 ET10037.73
01:24 ET20037.73
01:26 ET80037.725
01:28 ET170037.76
01:32 ET30037.83
01:33 ET10037.81
01:35 ET460437.82
01:37 ET10037.9
01:39 ET30037.84
01:44 ET30037.84
01:50 ET68837.84
01:51 ET10037.86
01:53 ET10037.82
01:57 ET10037.87
02:00 ET10037.84
02:02 ET40037.8
02:06 ET50037.75
02:08 ET10037.75
02:09 ET30037.8
02:11 ET20037.8
02:13 ET10037.78
02:15 ET100037.8
02:31 ET111937.75
02:44 ET30037.83
02:45 ET20037.84
02:51 ET22937.8007
02:54 ET30037.84
02:56 ET50037.89
03:00 ET20037.825
03:02 ET50037.82
03:03 ET90037.87
03:05 ET250037.91
03:07 ET150037.905
03:12 ET471137.74
03:14 ET10537.75
03:18 ET50037.83
03:21 ET20037.79
03:25 ET10037.8
03:27 ET110037.84
03:30 ET50037.82
03:32 ET10037.81
03:36 ET24937.83
03:38 ET70037.86
03:39 ET56737.85
03:41 ET20037.85
03:43 ET340037.88
03:45 ET21237.895
03:48 ET59837.93
03:50 ET185738
03:52 ET252338.01
03:54 ET347538
03:56 ET642537.905
03:57 ET368637.85
03:59 ET505437.68
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesXENE
Xenon Pharmaceuticals Inc
2.9B
-13.9x
---
United StatesSWTX
SpringWorks Therapeutics Inc
2.9B
-7.8x
---
United StatesBHVN
Biohaven Ltd
2.9B
-4.9x
---
United StatesDYN
Dyne Therapeutics Inc
3.1B
-7.8x
---
United StatesIDYA
IDEAYA Biosciences Inc
2.9B
-19.0x
---
United StatesVSBC
Vitaspring Biomedical Co. Ltd
3.1B
3,311.3x
---
As of 2024-06-08

Company Information

Xenon Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company focused on developing therapeutics to improve the lives of patients with neurological disorders, with a focus on epilepsy. The Company’s product pipeline includes XEN1101 (Focal Onset Seizures), XEN1101 (Primary Generalized Tonic-Clonic Seizures), XEN1101 (Major Depressive Disorder) and NBI-921352 (NEUROCRINE). It is developing XEN1101, a differentiated Kv7 potassium channel opener, for the treatment of epilepsy, MDD and potentially other neurological disorders. Its XEN1101 Phase III epilepsy program includes two identical Phase III clinical trials, called X-TOLE2 and X-TOLE3, that are designed closely after the Phase IIb X-TOLE clinical trial. Its Phase III X-ACKT clinical trial is intended to support potential regulatory submissions in an additional epilepsy indication of primary generalized tonic-clonic seizures (PGTCS).

Contact Information

Headquarters
3650 Gilmore WayVANCOUVER, BC, Canada V5G 4W8
Phone
604-484-3300
Fax
604-484-3450

Executives

Chairman of the Board
Simon Pimstone
President, Chief Executive Officer, Director
Ian Mortimer
Chief Financial Officer
Sherry Aulin
Executive Vice President - Drug Discovery
James Empfield
Executive Vice President - Strategy and Innovation
Robin Sherrington

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$2.9B
Revenue (TTM)
$0.00
Shares Outstanding
75.5M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.27
EPS
$-2.71
Book Value
$12.31
P/E Ratio
-13.9x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.